Ethris GmbH, a leading biotechnology company pioneering transformative messenger RNA (mRNA) therapeutics, announced today that it has raised $26.3 Million (€23.3 Million) in a Series B financing round led by Laureus Capital.
Ethris GmbH announced today that its lead COVID-19 therapeutic candidate, ETH47, has been awarded “The Most Innovative Product Top 3” in the category of Leap Innovations at the Pharma Trend Image & Innovation Awards 2021.
Ethris’ existing collaboration with the Munster University Hospital has been awarded a research grant by the Central Innovation Program for SMEs (ZIM). The funding will help accelerate the joint research project in primary ciliary dyskinesia (PCD), including evaluation of ETH42, a first-in-class SNIM®RNA product in preclinical development.
Ethris announced the expansion of the company’s leadership team by the addition of Thomas Langenickel, M.D. in the role of Chief Medical Officer. Dr. Langenickel joined Ethris from Novartis AG, where he was Executive Director and Head of Respiratory Profiling within the Translational Medicine Group.
Ethris adapted the responsibilities among its leadership team to position the company for the next phase of its development. As a result, Dr. Gita Dittmar took on the role as Chief Executive Officer, PD Dr. Carsten Rudolph became Chief Scientific Officer and Prof. Dr. Christian Plank became Chief Technology Officer.
Ethris and AstraZeneca signed a five-year strategic research collaboration that is focused on developing new stabilized non-immunogenic modified RNA therapies for respiratory diseases using Ethris’ proprietary SNIM®RNA technology. Ethris received €25 million upfront plus research funding and is eligible for future research and development milestones, including sales related royalties upon commercialization.
Ethris announced the publication of a research paper in the peer-reviewed journal “Biomaterials” that underlines the broad therapeutic potential of the company’s proprietary mRNA transcript therapy platform. The paper demonstrates that a modified mRNA construct based on Ethris’ technology coding for the human growth factor BMP-2 (bone morphogenetic protein-2) can induce bone regeneration in three different settings including an established in-vivo model for bone healing.
Ethris has joined the cmRNAbone consortium of 11 European partners working to develop chemically modified RNAs and a specific vector delivery system as a novel bone regenerative therapy for trauma and osteoporosis patients. The [...]
Ethris has joined the consortium REANIMA led by the Spanish Centro Nacional de Investigaciones Cardiovasculares (CNIC), which will receive €8 million in funding over the next 5 years. The central goal of the REANIMA [...]
Ethris and its partners 20Med Therapeutics, the AO Research Institute Davos and Paracelsus Medical University have received a Eurostars grant to be used to further the development of a novel approach to treating osteoarthritis. [...]
Ethris scientific partners have published a paper on non-viral gene delivery using a polyoxamine-based co-polymer nanoparticle and the impact on long-term restoration of the CFTR gene in in vivo models of cystic fibrosis. We [...]